Treatment of Neurological diseases

Treatment of Neurodegenerative Diseases

Neurodegenerative diseases are a group of disorders characterized by the progressive loss of neuronal function and structure in the central or peripheral nervous system, leading to cognitive, motor and behavior impairments. These diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), pose significant challenges to quality of life, placing a significant strain on individuals, families and healthcare systems due to their complex pathophysiology and limited therapeutic options.

GoldenNeuro is currently focusing on Parkinson’s disease.

Parkinson’s Disease is progressive and neurodegenerative, affecting 10 million people worldwide, that currently has no cure.
There is an urgent need for effective therapies to address the debilitating symptoms and underlying causes of the disease.

GoldenNeuro (GN) is a fully equipped biotech startup that is attempting to solve the treatment of the devastating age-related neurodegenerative disease, Parkinson’s (PD).
We are tackling a certain form of PD (10% of patients) by targeting its genetic source—not treating its symptoms. There is no product on the market that can do this.
In the US, billions of dollars are spent each year caring for these patients. GN is developing delivery vehicles that potentially can carry the genetic medicine to the patient’s brain cells and genetically replace the defective enzyme and restore normal function
There is currently no product on the market that treats one of the underlying causes of PD
There are medications (e.g., Levodopa) that manage symptoms and potentially prolong the lives of patients.
In more detail, greater than 10% of the PD population has a defect in the gene that makes an enzyme called GCase—loss of this enzyme leads to PD. Our product would carry the genetic medicine of GCase into the defective neuronal cells and restore their function.